RE: GRANT OF OPTIONS – Director dealings26 Aug 2020 19:44
Thanks Guys
I found this relating to my question on Tizians website :-
John Brancaccio
Non-Executive Director
Mr. Brancaccio, retired CPA, is a financial executive with extensive international and domestic experience in pharmaceutical and biotechnology for privately and publicly held companies. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies.
Mr. Brancaccio is currently a director of Cardiff Oncology, Inc., Rasna Therapeutics, Inc., OKYO Pharma LTD and Hepion Pharmaceuticals, Inc.
So he is currently a director of OKYO Pharma and Cardiff Oncology,Hepion Pharmaceuticals, Inc.
I read somewhere that OKYO Pharma was connected somehow to Tils ? Thoughts anyone ?